Cargando…

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

BACKGROUND: Sodium–glucose cotransporter 2 inhibitors reduce hospitalizations for heart failure and cardiovascular death, although the underlying mechanisms have not been resolved. The SIMPLE trial (The Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jürgens, Mikkel, Schou, Morten, Hasbak, Philip, Kjær, Andreas, Wolsk, Emil, Zerahn, Bo, Wiberg, Mikkel, Brandt‐Jacobsen, Niels H., Gæde, Peter, Rossing, Peter, Faber, Jens, Inzucchi, Silvio E., Gustafsson, Finn, Kistorp, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475664/ https://www.ncbi.nlm.nih.gov/pubmed/34278803 http://dx.doi.org/10.1161/JAHA.120.020418

Ejemplares similares

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial
por: Brandt-Jacobsen, Niels, et al.
Publicado: (2022)

Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
por: Brandt‐Jacobsen, Niels H., et al.
Publicado: (2023)

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve
por: Holmager, Pernille, et al.
Publicado: (2017)

Uric acid in advanced heart failure: relation to central haemodynamics and outcome
por: Deis, Tania, et al.
Publicado: (2022)

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)
por: Omar, Massar, et al.
Publicado: (2022)

Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome
por: Deis, Tania, et al.
Publicado: (2019)

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
por: Rasmussen, Jon Jarløv, et al.
Publicado: (2016)

Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial
por: H. Brandt-Jacobsen, Niels, et al.
Publicado: (2023)

MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction
por: Jensen, Jesper, et al.
Publicado: (2020)

Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)
por: Parveen, Saaima, et al.
Publicado: (2022)

Myocardial flow reserve assessed by cardiac (82)Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes
por: Zobel, Emilie H, et al.
Publicado: (2019)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure
por: Bosselmann, Helle, et al.
Publicado: (2017)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction
por: Christensen, Heidi M, et al.
Publicado: (2013)

Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation
por: Refsgaard Holm, Maria, et al.
Publicado: (2019)

Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure
por: Stoltze Gaborit, Freja, et al.
Publicado: (2016)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Treatment of subclinical hyperthyroidism: effect on left ventricular mass and function of the heart using magnetic resonance imaging technique
por: Mark, Peter D, et al.
Publicado: (2015)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct‐acting antiviral treatment—a pilot study
por: Sølund, Christina, et al.
Publicado: (2022)

Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by (82)Rb PET/CT in HIV-Infected Patients
por: Ørbæk, Mathilde, et al.
Publicado: (2017)

Coronary flow velocity reserve by echocardiography: feasibility, reproducibility and agreement with PET in overweight and obese patients with stable and revascularized coronary artery disease
por: Olsen, Rasmus Huan, et al.
Publicado: (2016)

MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail
por: Kistorp, Caroline, et al.
Publicado: (2019)

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
por: Ruggenenti, Piero, et al.
Publicado: (2021)

Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R(+) T cells
por: von Scholten, Bernt Johan, et al.
Publicado: (2016)

Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study
por: Westin, Oscar, et al.
Publicado: (2021)

Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study
por: Jensen, Jesper, et al.
Publicado: (2023)

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
por: Zinman, Bernard, et al.
Publicado: (2017)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study
por: Gaborit, Freja Stoltze, et al.
Publicado: (2020)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
por: Fitchett, David, et al.
Publicado: (2019)

Quantifying the Influence of Surface Texture and Shape on Structure from Motion 3D Reconstructions
por: Nielsen, Mikkel Schou, et al.
Publicado: (2022)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes
por: Inzucchi, Silvio E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lprpke2nqh56ast9p3bp957kfi